A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)
NCT ID: NCT02147938
Last Updated: 2024-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
578 participants
OBSERVATIONAL
2014-07-17
2017-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Analysis of two groups of patients: patients converted from Prograf® to Advagraf® early (during the first 6 months post-transplantation) or late (between 6 and 12 months post-transplantation).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year
NCT02143479
A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF
NCT01839929
A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients
NCT01742676
Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients
NCT02555787
Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients
NCT01476488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1: early conversion from Prograf® to Advagraf®
patients converted during the first 6 months post-transplantation
Tacrolimus
oral
2: late conversion from Prograf® to Advagraf®
patients converted between 6 and 12 months post-transplantation
Tacrolimus
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus
oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient where the conversion from Prograf® to Advagraf® has been decided by the doctor
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma S.A.S.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical and Scientific Affairs Manager, Transplantation
Role: STUDY_DIRECTOR
Astellas Pharma S.A.S.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site
Amiens, , France
Site
Angers, , France
Site
Besançon, , France
Site
Brest, , France
Site
Caen, , France
Site
Clermond-Ferrand, , France
Site
Créteil, , France
Site
Dijon, , France
Site
Le Krémlin-Bicêtre, , France
Site
Lille, , France
Site
Limoges, , France
Site
Lyon, , France
Site
Marseille, , France
Site
Montpellier, , France
Site
Nancy, , France
Site
Nantes, , France
Site
Nice, , France
Site
Paris, , France
Site
Poitiers, , France
Site
Rennes, , France
Site
Rouen, , France
Site
Saint-Etienne, , France
Site
Strasbourg, , France
Site
Suresnes, , France
Site
Toulouse, , France
Site
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FR-ADV-NI-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.